Q1 Earnings Forecast for FHTX Issued By Wedbush

Key Points

• Wedbush analysts forecast Foghorn Therapeutics Inc. will report Q1 2026 earnings of ($0.25) per share, with a full-year estimate of ($1.55) per share.
• Foghorn Therapeutics recently beat earnings expectations, reporting ($0.28) EPS for its last quarter, surpassing the consensus estimate of ($0.31) by $0.03.
• The company has a current consensus rating of "Buy" and a price target of $12.13, with eight analysts recommending buy or outperform ratings.

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Research analysts at Wedbush issued their Q1 2026 earnings estimates for shares of Foghorn Therapeutics in a research note issued on Tuesday, August 5th. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($0.25) for the quarter. The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($1.55) per share. Wedbush also issued estimates for Foghorn Therapeutics' Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.23) EPS and Q4 2026 earnings at ($0.23) EPS.

Several other research analysts have also recently weighed in on the stock. Citizens Jmp started coverage on shares of Foghorn Therapeutics in a report on Wednesday, April 23rd. They set a "mkt outperform" rating and a $9.00 price objective for the company. JMP Securities reaffirmed a "market outperform" rating and set a $9.00 target price on shares of Foghorn Therapeutics in a report on Thursday, May 15th. Citigroup started coverage on shares of Foghorn Therapeutics in a report on Wednesday, April 23rd. They set an "outperform" rating for the company. Finally, HC Wainwright raised shares of Foghorn Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $12.00.

Foghorn Therapeutics Stock Performance

Shares of FHTX traded down $0.40 during mid-day trading on Wednesday, hitting $4.58. 71,553 shares of the company traded hands, compared to its average volume of 122,213. The stock has a 50-day moving average price of $5.13 and a two-hundred day moving average price of $4.59. Foghorn Therapeutics has a 1 year low of $2.94 and a 1 year high of $10.25. The stock has a market cap of $258.91 million, a price-to-earnings ratio of -3.85 and a beta of 3.05.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.03. The business had revenue of $7.56 million for the quarter, compared to the consensus estimate of $7.62 million.

Hedge Funds Weigh In On Foghorn Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in Foghorn Therapeutics by 14.5% during the fourth quarter. Bank of America Corp DE now owns 31,662 shares of the company's stock valued at $149,000 after purchasing an additional 4,002 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its position in Foghorn Therapeutics by 44.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 100,367 shares of the company's stock valued at $474,000 after purchasing an additional 30,671 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Foghorn Therapeutics during the fourth quarter valued at $61,000. Lazard Asset Management LLC bought a new position in Foghorn Therapeutics during the fourth quarter valued at $49,000. Finally, Geode Capital Management LLC lifted its position in Foghorn Therapeutics by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 682,863 shares of the company's stock valued at $3,224,000 after purchasing an additional 5,477 shares during the last quarter. Institutional investors own 61.55% of the company's stock.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.